BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27981301)

  • 1. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
    Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.
    Tabibian JH; Weeding E; Jorgensen RA; Petz JL; Keach JC; Talwalkar JA; Lindor KD
    Aliment Pharmacol Ther; 2013 Mar; 37(6):604-12. PubMed ID: 23384404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
    Davies YK; Cox KM; Abdullah BA; Safta A; Terry AB; Cox KL
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):61-7. PubMed ID: 18607270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
    Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid for primary sclerosing cholangitis.
    Chazouillères O; Poupon R; Capron JP; Metman EH; Dhumeaux D; Amouretti M; Couzigou P; Labayle D; Trinchet JC
    J Hepatol; 1990 Jul; 11(1):120-3. PubMed ID: 1975818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
    Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [No Abstract]   [Full Text] [Related]  

  • 16. Type 2 autoimmune hepatitis overlapping with primary sclerosing cholangitis in a 10-year-old boy.
    Gargouri L; Mnif L; Safi F; Turki F; Majdoub I; Maalej B; Bahri I; Mnif H; Boudawara T; Tahri N; Mahfoudh A
    Arch Pediatr; 2013 Dec; 20(12):1325-8. PubMed ID: 24182664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
    van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
    J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
    J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
    Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
    Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.